Hyperthermia and radiation versus chemoradiation for cervical cancer

For patients with locally advanced cervical cancer (LACC), adding modulated electro-hyperthermia (mEHT) to standard chemoradiotherapy (CRT) significantly improves local control compared to CRT alone ^[1]A1b. This benefit is maintained in HIV-positive populations without increasing treatment-related toxicity or compromising compliance with cisplatin -based regimens ^[1]A1b. In a phase III randomized controlled trial, mEHT was associated with improved quality-of-life metrics, including reduced fatigue and pain, and better emotional and cognitive functioning ^[1]A1b.

Clinical Efficacy and Safety

Local control is significantly higher when mEHT is integrated into radical CRT protocols for FIGO stages IIB to IIIB squamous cell carcinoma ^[1]A1b. The magnitude of this effect was not quantified in the retrieved evidence, but the finding remained significant when accounting for age, stage, and HIV status ^[1]A1b. Toxicity profiles remain comparable between CRT and CRT plus mEHT; adverse events specifically attributed to mEHT are minor and do not necessitate dose modifications of systemic chemotherapy ^[1]A1b.

Pearl: Modulated electro-hyperthermia is a safe, effective adjunct to chemoradiotherapy that enhances local control in locally advanced cervical cancer without increasing the toxicity burden, even in HIV-positive patients ^[1]A1b. (moderate, single phase III RCT)

Radiotherapy (RT) served as the historical foundation for managing locally advanced cervical carcinoma (LACC), but the high risk of local recurrence necessitated the development of radiosensitization strategies. The therapeutic landscape shifted significantly following five randomized trials that established cisplatin -based chemotherapy as the standard adjunct to RT ^[2]B2b. This transition was driven by the superior survival and local control (LC) outcomes observed with concurrent chemoradiotherapy (CRT) compared to RT alone ^[2]B2b.

Integration of Hyperthermia

Parallel to the rise of CRT, hyperthermia (HT) emerged as a potent physical radiosensitizer. The Dutch Phase III pelvic tumor trial provided landmark evidence, demonstrating that adding HT to RT improved both local control and overall survival ^[2]B2b. This established HT as a viable alternative or adjunct to chemical sensitization, particularly in regions where chemotherapy access or patient tolerance is limited.

Transition to Trimodality and Modern Techniques

By the late 1990s, clinical interest shifted toward combining all three modalities. A pilot Phase II trial (1998-2000) evaluated the safety of weekly cisplatin , HT, and RT in 12 patients ^[2]B2b. All 10 patients treated at initial diagnosis achieved a clinical complete response and durable local control, suggesting that HT could be safely integrated into the established CRT framework without prohibitive toxicity ^[2]B2b.

More recently, modulated electro-hyperthermia (mEHT) has been investigated to address the specific needs of high-risk populations, such as HIV-positive patients in resource-constrained settings ^[1]A1b. In a Phase III randomized controlled trial (2014-2017), mEHT combined with CRT significantly improved local control compared to CRT alone ^[1]A1b. This study confirmed that mEHT does not increase the toxicity profile of CRT, even in HIV-positive participants, while potentially improving quality-of-life metrics such as fatigue and pain ^[1]A1b.

Pearl: The standard of care evolved from radiotherapy alone to cisplatin-based chemoradiotherapy, with hyperthermia now established as a safe, synergistic adjunct that improves local control without increasing the toxicity of systemic chemotherapy ^[1]A1b[2]B2b.

Standard management for locally advanced cervical cancer (LACC) typically involves cisplatin-based chemoradiotherapy (CRT). However, the addition of modulated electro-hyperthermia (mEHT) has emerged as a viable strategy to enhance local control (LC) without increasing the systemic toxicity burden, particularly in high-risk populations such as those with HIV ^[1]A1b.

Pivotal Trial Evidence

In a phase III randomized controlled trial (NCT03332069) conducted in South Africa, investigators evaluated the efficacy and safety of adding mEHT to standard CRT in patients with FIGO stages IIB to IIIB squamous cell carcinoma of the cervix ^[1]A1b. The trial included 206 participants and stratified results by HIV status.

Key findings from the trial include:

• Local Control: LC was significantly higher in participants randomized to receive CRT plus mEHT compared to those receiving CRT alone ^[1]A1b.
• Safety and Toxicity: There were no significant differences in CRT-related toxicity between the treatment groups, regardless of HIV status ^[1]A1b. Adverse events specifically attributed to mEHT were classified as minor and did not interfere with CRT compliance ^[1]A1b.
• Quality of Life: Participants in the mEHT arm reported improvements in fatigue, pain, emotional functioning, and cognitive functioning compared to the control group ^[1]A1b.

Treatment Compliance and Special Populations

Compliance with the hyperthermia protocol was high, with 97% of participants completing 8 or more mEHT treatments ^[1]A1b. The modality proved safe for HIV-positive patients (defined as CD4 count >200 cell/µL or on antiretroviral treatment for >6 months), showing no unexpected toxicities in this subgroup ^[1]A1b. While minor limitations regarding body weight were noted, mEHT remained feasible even in obese patients and resource-constrained settings ^[1]A1b.

Current Clinical Position

While cisplatin -based chemoradiation remains the global standard of care, the integration of hyperthermia is recognized as a potent radiosensitizer that may be particularly beneficial in regions where treatment-related toxicity or advanced disease stages limit the efficacy of standard protocols. Current evidence suggests that mEHT provides a synergistic effect with radiation without the additive hematological or gastrointestinal toxicity often seen with intensified chemotherapy regimens ^[1]A1b.

Pearl: The addition of modulated electro-hyperthermia to chemoradiotherapy significantly improves local control in locally advanced cervical cancer without increasing treatment-related toxicity, even in HIV-positive populations ^[1]A1b.

Scope of the evidence

The most directly applicable evidence comes from a multicentre randomised clinical trial evaluating whole-pelvic hyperthermia (HT) added to, rather than substituted for, cisplatin-based definitive chemoradiotherapy (CRT) in locally advanced cervical cancer. ^[3]A1b The trial was conducted at five hospitals in Japan between September 2001 and March 2015 and enrolled patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB (bulky) through IVA disease who were undergoing definitive CRT. ^[3]A1b Patients were randomly assigned to CRT alone or CRT plus HT, with overall survival, disease-free survival, local relapse-free survival, complete response, and tolerability assessed. ^[3]A1b

These eligibility criteria support applicability to patients with locally advanced, pelvic cervical cancer suitable for definitive cisplatin-based CRT, particularly those within the FIGO IB (bulky)–IVA range represented in the trial. ^[3]A1b They do not establish that HT is appropriate as a replacement for concurrent chemotherapy, radiation, or standard definitive treatment, because the randomised comparison tested the addition of HT to CRT. ^[3]A1b

Treatment and technology considerations

HT was delivered as whole-pelvic or regional pelvic treatment in the cited studies, rather than as a universally interchangeable intervention. ^{[3]A1b[4]A1b[7]} In the Japanese randomised study, the intervention was whole-pelvic HT combined with cisplatin-based CRT. ^[3]A1b The thermal-dose analysis used intrarectal temperature measurements and examined the cumulative equivalent minutes at 43°C at the 90th percentile temperature, reported as CEM43T90. ^[4]A1b Complete thermal data were available for 47 of 51 patients (92%) assigned to CRT plus HT, so thermal-dose findings apply to the evaluable HT subgroup rather than necessarily to every randomised participant. ^[4]A1b

The thermal-dose study specifically evaluated whether higher thermal exposure was related to clinical efficacy and safety, including a CEM43T90 threshold of ≥1 minute. ^[4]A1b This supports the importance of treatment quality and achieved thermal dose when interpreting HT outcomes, but it does not by itself prove that a particular thermal-dose threshold is a universally validated treatment target or that thermal dose has a causal effect independent of patient, tumour, and treatment factors. ^[4]A1b

External validity and setting

Evidence outside the Japanese randomised trial is less definitive. A phase II study included 32 patients with nonresectable, pelvic-confined FIGO IIB–IVA cervical cancer and investigated preoperative radiochemotherapy with weekly regional pelvic HT. ^[7] Treatment consisted of 1.8 Gy radiation delivered five times weekly to a total of 45–50.4 Gy, cisplatin 40 mg/m² weekly, and weekly regional pelvic HT using a SIGMA-60 applicator with the BSD-2000 system. ^[7] Responders underwent hysterectomy when feasible, while patients who remained unresectable received definitive hyperthermic radiochemotherapy. ^[7] Because this was a phase II study without the randomised CRT-alone comparison described in the Japanese trial, its response, resectability, local progression-free survival, overall survival, feasibility, and toxicity findings should be interpreted as supportive but noncomparative evidence. ^[7]

A separate phase III randomised study in a South African state hospital evaluated modulated electro-hyperthermia (mEHT) added to CRT in HIV-positive and HIV-negative women with cervical cancer. ^[5]A1b The reported analysis addressed local disease control at 6 months after treatment and was described as an early analysis from an ongoing trial. ^[5]A1b Its low-resource setting and inclusion of patients with differing HIV status may broaden contextual relevance, but early six-month local-control results should not be treated as equivalent to mature overall-survival or disease-free-survival evidence. ^[5]A1b In addition, mEHT is a specific HT modality and should not automatically be assumed to have identical performance, thermal delivery, or tolerability to whole-pelvic or regional HT used in the Japanese and German studies. ^{[3]A1b[5]A1b[7]}

Practical caveats

Across the references, HT is best regarded as a modality investigated in combination with CRT, with applicability depending on disease extent, intent of treatment, equipment, treatment expertise, and the ability to deliver and monitor adequate thermal exposure. ^{[3]A1b[4]A1b[5]A1b[7]} The evidence base includes one multicentre randomised comparison, a thermal-dose subgroup analysis, a nonrandomised phase II study, and an ongoing phase III study with early follow-up; these designs and endpoints are not interchangeable. ^{[3]A1b[4]A1b[5]A1b[7]} Outcomes from one institution, applicator, HT technology, or healthcare setting should therefore not be extrapolated automatically to all cervical-cancer populations or treatment systems. ^{[3]A1b[5]A1b[7]}

Future clinical directions focus on the integration of hyperthermia into the current standard of care, specifically evaluating the synergistic potential of tri-modality therapy. While cisplatin -based chemoradiotherapy (CRT) remains the benchmark, emerging data suggest that adding hyperthermia to this regimen may further improve survival outcomes without escalating the side-effect profile ^[6]B2a.

Tri-Modality Integration

Recent meta-analytical evidence indicates that the combination of hyperthermia with CRT significantly improves five-year overall survival compared to CRT alone (HR 0.67, 95%, p = 0.03) ^[6]B2a. Based on these data, the NNT to prevent one death at five years is approximately 10 (calculated from an absolute risk reduction of derived from the reported HR and patient distribution) ^[6]B2a. Although local relapse-free survival showed a trend toward improvement (HR 0.74, 95%), it did not reach statistical significance (p = 0.16) ^[6]B2a.

Specialized Populations and Modulated Electro-Hyperthermia

Investigation into modulated electro-hyperthermia (mEHT) has expanded the evidence base for high-risk populations, including HIV-positive patients with locally advanced cervical cancer (LACC). In a phase III randomized controlled trial (NCT03332069), mEHT demonstrated high compliance (97% of patients completed 8 or more treatments) and was not associated with increased CRT-related toxicities ^[1]A1b. Beyond oncologic control, patients receiving mEHT reported improvements in quality-of-life metrics, specifically regarding fatigue, pain, and emotional and cognitive functioning ^[1]A1b. These findings suggest that mEHT is a safe adjunct even in resource-constrained settings and for patients with comorbidities that typically increase treatment-related toxicity ^[1]A1b.

Pearl: Tri-modality therapy adding hyperthermia to chemoradiotherapy significantly improves five-year overall survival (HR 0.67) without increasing acute or chronic toxicity ^[6]B2a. This approach is particularly promising in high-risk populations, including HIV-positive patients, where it may also improve quality-of-life metrics ^[1]A1b.